MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

16.23 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
34 35 Next >
News headline image
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. 
Via Benzinga
Topics Stocks
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
News headline image
2 Growth Stocks That Could Make You Richer in 2024 and Beyond ↗
Last year wasn't great for either stock, but that's no reason to ignore them. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
The Latest Analyst Ratings for Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
Could Sarepta Therapeutics Stock Help You Become a Millionaire? ↗
Can this struggling stock turn its fortunes around? 
Via The Motley Fool
News headline image
Analyst Ratings for Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
News headline image
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024 ↗
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech... 
Via Talk Markets
News headline image
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 ↗
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
News headline image
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
1 Gene Therapy Stock to Buy and Hold for the Long Haul ↗
The biotech has what it takes to overcome recent obstacles. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
3 Things About Sarepta Therapeutics Every Smart Investor Knows ↗
Mastering this stock requires appreciating a few scientific nuances. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? ↗
Both develop medicines for rare diseases, and each aims to conquer a niche market. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond ↗
Many investors are bailing out, but that might be a mistake. 
Via The Motley Fool
News headline image
My Take: 4 Strong Growth Stocks to Buy This Week ↗
These strong stocks are still available at a great price. That may not be the case a whole lot longer. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
3 Monster Stocks in the Making ↗
These stocks could grow much larger over the next few years. 
Via The Motley Fool
News headline image
3 Stocks You’ll Regret Not Buying Soon: November 2023 ↗
These stocks to buy are the ones to scoop up soon for long-term growth as these companies have stable growth catalysts in the coming years. 
Via InvestorPlace
News headline image
SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy ↗
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the  
Via Benzinga
News headline image
Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got incredible growth, and people like growth again. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Is Sarepta Therapeutics Stock a Bad-News Buy? ↗
Analysts still expect some sizable returns from the stock. 
Via The Motley Fool
News headline image
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks? ↗
Just because a stock is "on sale" doesn't inherently make it worth purchasing. 
Via The Motley Fool
News headline image
SRPT LOSS ALERT: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story